Soleno Therapeutics Inc.

70.12
1.19 (1.73%)
At close: Apr 22, 2025, 11:51 AM
1.73%
Bid 70
Market Cap 3.22B
Revenue (ttm) n/a
Net Income (ttm) -175.85M
EPS (ttm) -4.38
PE Ratio (ttm) -16.01
Forward PE 6998
Analyst Buy
Ask 70.18
Volume 272,867
Avg. Volume (20D) 1,163,078
Open 69.10
Previous Close 68.93
Day's Range 69.41 - 70.51
52-Week Range 36.93 - 74.00
Beta -2.29

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its n...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2014
Employees 92
Stock Exchange NASDAQ
Ticker Symbol SLNO
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for SLNO stock is "Buy." The 12-month stock price forecast is $102, which is an increase of 45.46% from the latest price.

Stock Forecasts
3 weeks ago
+6.83%
Soleno Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
3 weeks ago
+37.61%
Soleno Therapeutics shares are trading higher after the company announced it secured FDA approval for its first commercial drug for a rare genetic disorder.